Herbal supplements direct-seller Nature's Sunshine Q3 revenue beats estimates, powered by digital sales growth

Nature's Sunshine Products

06/11/2025 22:19

Overview

Nature's Sunshine Products Q3 net sales up 12% to $128.3 mln, beating analyst expectations

Adjusted EBITDA for Q3 rises 42% to $15.2 mln, exceeding analyst estimates

Company raises full-year outlook for 2025 net sales and adjusted EBITDA

Outlook

Natures Sunshine raises 2025 net sales forecast to $476-$480 mln from $460-$475 mln

Company increases 2025 adjusted EBITDA guidance to $47-$49 mln from $41-$45 mln

Result Drivers

DIGITAL SALES - Strategic investments in North America Digital led to a 52% increase in digital sales

ASIA-PACIFIC GROWTH - Exceptional results in Asia-Pacific driven by 30%+ growth in Japan and China

COST SAVINGS - Cost-saving initiatives increased gross margin by 200 basis points to 73.3%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$128.30 mln
$120.30 mln (2 Analysts)
Q3 Net Income
$5.30 mln
Q3 Adjusted EBITDA
Beat
$15.20 mln
$10.49 mln (2 Analysts)
Q3 Gross Margin
73.30%
Q3 Operating Income
$9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the food processing peer group is "buy"

Wall Street's median 12-month price target for Nature's Sunshine Products Inc is $21.50, about 34.3% above its November 5 closing price of $14.13

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nGNX5p3vtv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)